Psychiatric comorbidity is common in dystonia and other movement disorders

Michelle S. Lorentzos PhD^{*1}, Isobel Heyman FRCPsych PhD², Benjamin J. Baig MRCPsych PhD², Anna E. Coughtrey PhD², Andrew McWilliams MRCPsych², David R. Dossetor FRCPsych³, Mary-Clare Waugh FRACP⁴, Ruth A. Evans⁴, Josie Hollywood², Joshua Burns PhD⁵, Manoj P. Menezes PhD^{1,5}, Shekeeb S. Mohammad PhD^{1,5}, Padraic Grattan-Smith FRACP¹, Kathleen M. Gorman MRCPI², Belinda HA Crowe MRCPCH⁶, Robert Goodman PhD FRACPsych², Manju A. Kurian PhD², Russell C. Dale PhD^{1,5}

¹TY Nelson Department of Neurology and Neurosurgery, ³Psychological Medicine, and ⁴Kids Rehab, The Children's Hospital at Westmead,

²Developmental Neurosciences, ⁶the Wolfson Neurodisability Service, Great Ormond Street Institute of Child Health and Great Ormond Street Hospital for Children NHS Foundation Trust, University College London, UK

⁵Kids Neuroscience Centre at Kids Research, Brain and Mind Centre, Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney

Correspondence:

Professor Russell Dale, Clinical School, the Children's Hospital at Westmead, Locked Bag 4001, Westmead NSW 2145, Australia

T: +61 298450000 F: +61 298453389

Russell.dale@health.nsw.gov.au

Abstract 200 words Main manuscript 1847 words

18 references

5 tables, 1 figure

2 supplementary tables

Running title: Psychiatry of paediatric movement disorders Keywords: Psychiatry, dystonia, anxiety, comorbidity, child

Financial Disclosures or conflict of interest: Michelle S. Lorentzos-Reports no disclosures or conflict of interest Isobel Heyman- Reports no disclosures or conflict of interest Benjamin J. Baig- Reports no disclosures or conflict of interest Anna E. Coughtrey- Reports no disclosures or conflict of interest Andrew McWilliams- Reports no disclosures or conflict of interest David R. Dossetor- Reports no disclosures or conflict of interest Mary-Clare Waugh- Reports no disclosures or conflict of interest Ruth A. Evans- Reports no disclosures or conflict of interest Josie Hollywood- Reports no disclosures of conflict of interest Joshua Burns - Reports no disclosures or conflict of interest Manoj P. Menezes- Reports no disclosures or conflict of interest Shekeeb S. Mohammad- Reports no disclosures or conflict of interest Padraic Grattan-Smith- Reports no disclosures or conflict of interest Kathleen M. Gorman- Reports no disclosures or conflict of interest Belinda HA Crowe- Reports no disclosures or conflict of interest Robert Goodman- Reports no disclosures or conflict of interest Manju A. Kurian- Reports no disclosures or conflict of interest Russell C. Dale- Reports no disclosures or conflict of interest

Abstract

Objective: To determine rates of psychiatric comorbidity in a clinical sample of childhood movement disorders.

Design: Cohort study.

Setting: Tertiary children's Hospital Movement disorder clinics in Sydney, Australia and London, UK.

Patients: Cases were children with tic movement disorders (n=158) and non-tic movement disorders (MD) (n=102), including 66 children with dystonia. Comparison was made with emergency department controls (n=100), neurology controls with peripheral neuropathy or epilepsy (n=37), and community controls (n=10,438).

Interventions: On-line Development and Wellbeing Assessment (DAWBA) which was additionally clinically rated by experienced child psychiatrists.

Main outcome measures: DSM-5 criteria for psychiatric diagnoses.

Results: Psychiatric comorbidity in the non-tic MD cohort (39.2%) was comparable to the tic cohort (41.8%) (not significant). Psychiatric comorbidity in the non-tic MD cohort was greater than the emergency control group (18%, (p<0.0001) and the community cohort (9.5%, p<0.00001), but not the neurology controls (29.7%, p=0.31). Almost half of the patients within the tic cohort with psychiatric comorbidity were receiving medical psychiatric treatment (45.5%) or psychology interventions (43.9%), compared to only 22.5% and 15.0% respectively of the non-tic MD cohort with psychiatric comorbidity.

Conclusions: Psychiatric comorbidity is common in non-tic movement disorders such as dystonia. These psychiatric comorbidities appear to be under-recognised and under-treated.

Introduction

Psychiatric co-morbidities have been well described in adults with movement disorders such as Huntington's Disease and Wilson's Disease¹. Psychiatric comorbidity in children with tics and Tourette syndrome (TS) is also well described and is often more impairing than the tics themselves. However the investigation of psychiatric comorbidity in children with a broader range of movement disorders such as dystonia and chorea is limited to case reports and small case series.^{2, 3} Studies have consistently shown that children with long-term health conditions, especially neurological disorders such as epilepsy have elevated rates of psychiatric illness.⁴ In addition, common psychiatric disorders are increased in populations of physically unwell children, which can be effectively treated with wellestablished evidence-based treatments. ^{5, 6}

In Tourette's syndrome and tic disorders, there is better awareness of the high rates of psychiatric comorbidity and the impairment these cause, and national guidelines for the treatments of tics increasingly emphasise the importance of detection and treatment of comorbid mental health conditions. ⁷ However there is no such emphasis for non-tic movement disorders.

In this study a comparison was made between the rate of psychiatric comorbidity in children with non-tic movement disorders to children with tics and TS, as well as other control groups. We found that children with non-tic movement disorders have a similar rate of psychiatric comorbidity to children with tics and Tourette syndrome. We also established that, similar to children with other neurological disorders such as epilepsy, these children with non-tic movement disorders were much less likely to have their mental health needs detected and treated.⁸

Method

Patients: Patients were recruited according to inclusion criteria as follows: (1) age between 5 and 16 years (2) ability to speak in minimum of 5-word sentences, and (3) parental ability to speak English to allow for informed consent and questionnaire completion. Patients were recruited from The Children's Hospital at Westmead, Australia and Great Ormond Street Hospital, United Kingdom. We

recruited all eligible and sequential patients to avoid recruitment bias. Table 1 shows the baseline demographic data across all cohorts.

The tic movement disorder cohort consisted of patients with tics and Tourette Syndrome (n=158, including n=136 with TS). Within the non-tic movement disorder (MD) cohort (n=102), patients were diagnosed with either neurotransmitter disorders (n=13, GTP-cyclohydrolase deficiency, tyrosine hydroxylase deficiency and 6-PTPS deficiency), a proven genetic disorder (n=24, including KMT2B dystonia, TBC1D24 dystonia, SCGE myoclonus dystonia, GNB1 dystonia, glutaric aciduria type 1, paroxysmal kinesiogenic dystonia, benign hereditary chorea, Wilsons disease and Juvenile Huntington's disease), suspected genetic disorders (clinical course, imaging and/or family history compatible a genetic diagnosis however genetic testing negative, n=18), immune mediated movement disorders (n=11, including Sydenham's Chorea, antiphospholipid chorea, basal ganglia encephalitis, Rasmussen encephalitis, opsoclonus myoclonus syndrome and acute immune akinetic psychotic syndrome), dyskinetic cerebral palsy (n=22), developmental conditions such as stereotypy (n=11) or functional movement disorders (n=3). Further information of movement disorder phenomenology in the non-tic MD cohort is presented in Table 2.

To compare the findings in the movement disorder patients, we recruited an additional 137 patients from The Children's Hospital at Westmead, Australia to establish two clinical control groups: (1) an Emergency control cohort consisting of patients without neurological disease presenting to the Emergency Department for acute paediatric care (n=100), and (2) a Neurological disorder control cohort (n=37) consisting of patients without movement disorders but affected by peripheral neuropathy (n=25) or epilepsy without movement disorder (n=12). In addition, for further comparison, data from 10438 British children, who had completed the British Child and Mental Health Survey in 1999 using the same diagnostic tool (DAWBA- described below), were included as a community control group ⁹. Detailed intellectual assessment was not performed however school support was recorded. There was a low rate of special school needs in all of the cohorts, although there was a slightly elevated requirement for support in mainstream class for the non-tic group (Supplementary table 1).

Psychiatric assessment: All patients from all study groups were screened for psychiatric comorbidities using parental completion of the Development and Wellbeing Assessment Tool (DAWBA), an on-line self-completed questionnaire that has been validated previously, ^{9, 10} and generates DSM-5 diagnoses from a computer algorithm. The DAWBA questionnaires were additionally clinically rated by experienced child psychiatrists. The community cohort of 10438 children from the UK had been assessed with the same DAWBA tool in 1999 ⁹.

Statistics: Chi square probabilities were calculated to determine statistical validity of prevalence rates between groups.

Ethics and Data-sharing statement: Anonymized data will be shared by request from any qualified investigator. Ethical approval was received from the institutional review board (11CHW14).

Results

The rate of any DSM-5 psychiatric diagnosis in the tic cohort was 41.8% (n=66/158), compared with 39.2% (n=40/102) in the non-tic MD cohort (no statistically significant difference, p=0.68). The rate of psychiatric comorbidity in the non-tic MD cohort was significantly higher than the Emergency cohort (39.2% vs 18%, p<0.0001), and those in the UK community cohort (39.2% v. 9.5%, p<0.00001), but not higher than the neurology control group (39.2% v. 29.7%, p=0.31). Table 3 provides all DSM-5 psychiatric diagnoses according to the different cohorts. Figure 1 depicts the statistical differences between the non-tic MD cohort and other cohorts in terms of any psychiatric DSM-5 disorder, any anxiety disorder, any disruptive disorder, and any oppositional/conduct disorder. Supplementary Table 2 presents the number of DSM-5 diagnoses (1, 2, 3, 4, or more diagnoses). Table 4 details the psychiatric comorbidity in the non-tic cohort according to aetiology. Anxiety disorder phenotype, and Table 5 presents psychiatric comorbidity according to aetiology. Anxiety disorders were the most frequent psychiatric diagnoses in the non-tic cohort.

Of the patients with tics who had a psychiatric comorbidity, 45.5% had received psychiatric medications, and 43.9% had received psychological therapy. By comparison, despite the fact the psychiatric comorbidity was similar in the non-tic MD cohort, 22.5% of the non-tic MD patients with psychiatric comorbidity had received psychiatric medications, and 15.0% had received psychological therapy.

Discussion

This study demonstrates that children with movement disorders are four times as likely to have a psychiatric diagnosis than children in the general community. We show that children with non-tic movement disorders, including dystonia and chorea, have similar rates of psychiatric comorbidity as children with tics. Specifically, of the 66 patients with primary or secondary dystonia, 33.3% had a psychiatric comorbidity. Emotional disorders such as anxiety were the most dominant psychiatric comorbidity in all movement disorder patients.

An interesting finding in this study related to therapies provided to the tic and non-tic MD cohorts. Despite the similar psychiatric comorbidity in the tic and non-tic MD cohort, the rate of psychiatric medical or psychological therapies was significantly lower in the non-tic MD group. Although we cannot determine if the level of impairment in the tic and non-tic MD cohorts were identical, this does suggest that psychiatric comorbidity in non-tic MD patients is currently under-recognised and potentially under-treated. This heterogeneous group of movement disorders provides an additional example of groups of children with physical ill-health who should receive timely access to appropriate mental health interventions where needed ¹¹.

One of the strengths of the study was the recruitment of control groups and the use of the same standardised diagnostic tool for all patient and control groups. The large community study in the UK found a rate of 9% psychiatric disorder. We found higher psychiatric comorbidity in our hospital controls (emergency and neurology controls) compared to the community controls. The 'emergency' control cohort (n=100) found a higher rate of psychiatric comorbidity than the UK community control group (p<0.0001), which may be due to the fact children with acute injuries may have inherently more psychiatric comorbidity such as ADHD. Although the neurology control group was not the focus of this work, the elevated psychiatric comorbidity (29.7%) supports the need for further research and larger cohorts. Table 3 highlights the details of the psychiatric comorbidity in the neurology control group, with high rates of anxiety, depression, ADHD and social deficits,

whereas by contrast, obsessive-compulsive disorder and oppositional defiant disorder were not elevated in the neurology control group. The high rate of psychiatric comorbidity in the neurology control group raises the question of whether raised psychiatric comorbidity is a common feature of childhood neurological disease in general, rather than specific to movement disorders. Furthermore, the study methodology cannot determine if the elevated psychiatric comorbidity in the movement disorder patients is due to specific neural circuit disruption, or due to the burden of chronic impairing disease. Indeed, it is well described that adolescents with chronic disease such as diabetes, inflammatory bowel disease and asthma have increased psychiatric outcomes ¹².

A further confounder was the slightly elevated rate of educational adaptations in the non-tic cohort compared to the tic cohort and control groups, as it is recognised that intellectual disability is a risk factor for psychiatric comorbidity, however it should be noted that only 3 of the whole recruited patients required special school (2 in the tic group) (supplementary Table 2).

Overall the rates of psychiatric comorbidities in children with tic movement disorders children were lower than other studies, where comorbidities have been described in up to 90% ¹³. The DAWBA has been described as more conservative than other psychiatric screening tools such as the DISC and CAPA; in one study the DAWBA detected 1 or more diagnoses in 17.7% of patients in paediatric care clinics, whilst the DISC and CAPA diagnosed disorders in 47.1% and 32.4% respectively. ¹⁴ Several papers have suggested that the DAWBA tends to under-diagnose emotional disorders ^{15, 16}, and we observed an under-diagnosis of OCD in our cohorts. Therefore, we suspect that our cohort data should be considered a conservative approximation of psychiatric comorbidity in paediatric movement disorder cohorts.

The strengths of the study were the use of a standardized and validated tool to diagnose psychiatric comorbidity in patients and controls, and the recruitment of sequential patients therefore reducing selection bias. Weaknesses of the study were that despite the fact the non-tic cohort was moderately

large (n=102), the individual phenotypic and aetiological subgroups within the non-tic cohort were sometimes small, making subgroup conclusions difficult regarding the risk of psychiatric comorbidity. A further limitation was that the cohorts were recruited from two different centres in Australia and UK, although there was no psychiatric comorbidity difference between the patients recruited from the two countries (data not shown).

In conclusion, this study recognises that children with non-tic movement disorders are just as vulnerable to psychiatric comorbidities as children with tics and TS. Findings such as this add support to the increasing emphasis on developing services which fully integrate physical and mental health care. ¹⁷ This new evidence should encourage clinicians to screen for psychiatric comorbidities in all movement disorder (and all neurology) patients, therefore allowing earlier diagnosis and treatment. Although there are a number of tools available to the clinician, the Strengths and Difficulties Questionnaire (SDQ) is a validated screening tool, is quick to complete and assess, comes in 80 languages, and has no cost¹⁸. For patients that have identified problems using the SDQ, further assessment and treatment would depend on the services available in the patient's region, and experience of the screening clinician.

What is already known on this topic:

- 1. Psychiatric comorbidity is common in children with chronic diseases.
- 2. Psychiatric comorbidity is common in children with tic disorders and Tourette syndrome.

What this study adds:

- 1. Psychiatric comorbidity is not isolated to children with Tourette, but also with other non-tic movement disorders such as dystonia.
- **2.** Psychiatric comorbidity is less likely to be recognised, diagnosed and treated in children with non-tic movement disorders compared to Tourette syndrome.

Competing interests: None of the authors report a competing interest apart from Robert Goodman. Robert Goodman and his family are the owners of Youthinmind Limited, which provides no-cost and low-cost measures of child mental health, including the Strengths and Difficulties Questionnaire (SDQ) and the Development and Well-Being Assessment (DAWBA).

Acknowledgment: Petre Foundation, Cerebral Palsy Alliance Research Foundation

Contributorship statement: All listed authors have made substantial contributions to the conception or design of the work, drafting the work or critical revision, have approved final approval of the version to be published, and have agreed to be accountable for all aspects of the work (as per ICMJE guidelines).

Financial Disclosures of all authors (for the preceding 12 months)

Michelle S. Lorentzos- No financial disclosures

Isobel Heyman- No financial disclosures

Benjamin J. Baig- No financial disclosures

Anna E. Coughtrey- No financial disclosures

Andrew McWilliams- No financial disclosures

David R. Dossetor- No financial disclosures

Mary-Clare Waugh- No financial disclosures

Ruth A. Evans- No financial disclosures

Josie Hollywood- No financial disclosures

Joshua Burns is funded by the Australian Department of Health (Medical Research Future Fund), US National Institutes of Health, Charcot-Marie Tooth Association of Australia, Charcot-Marie Tooth Association (USA), Diabetes Australia, Elizabeth Lottie May Rosenthal Bone Bequest, Perpetual Limited, Humpty Dumpty Foundation. *Consultancies:* Pharnext SA, Charcot Marie Tooth Association (USA) Advisory Board (Clinical Experts), Research & Innovation Advisory Board, Siriraj Hospital, Mahidol University, Bangkok, Thailand

Manoj P Menezes. No financial disclosures

Shekeeb S Mohammad. No financial disclosures

Padraic Grattan-Smith- No financial disclosures

Kathleen M. Gorman- No financial disclosures

Belinda HA Crowe- No financial disclosures

Robert Goodman and his family are the owners of Youthinmind Limited, which provides nocost and low-cost measures of child mental health, including the Strengths and Difficulties Questionnaire (SDQ) and the Development and Well-Being Assessment (DAWBA).

Manju A. Kurian receives support from NIHR Research Professorship and Sir Jules Thorn Award

Russell C. Dale receives support from the Petre Foundation, National Health and Medical Research Council, Cerebral Palsy Alliance.

References

1. Ring HA, Serra-Mestres J. Neuropsychiatry of the basal ganglia. Journal of neurology, neurosurgery, and psychiatry 2002;72:12-21.

2. Ben-Pazi H, Jaworowski S, Shalev RS. Cognitive and psychiatric phenotypes of movement disorders in children: a systematic review. Developmental medicine and child neurology 2011;53:1077-1084.

3. Peall KJ, Lorentzos MS, Heyman I, et al. A review of psychiatric co-morbidity described in genetic and immune mediated movement disorders. Neuroscience and biobehavioral reviews 2017;80:23-35.

4. Davies S, Heyman I, Goodman R A population survey of mental health problems in children with epilepsy. Dev Med Child Neurol. 2003;45:292-5

5. Bennett, S., Shafran, R., Coughtrey, A., Walker, S., & Heyman, I. (2015). Psychological interventions for mental health disorders in children with chronic physical illness: A systematic review. *Archives of Disease in Childhood*, *100*(4), 308–316.

6. Bennett, S., Coughtrey, A. E., Heyman, I., Greally, S., Clarkson, H., Bhattacharyya, T., et al. (2018). Guided self-help for mental health disorders in children and young people with chronic neurological conditions: A qualitative evaluation. *European Journal of Paediatric Neurology*,22(4), 620–631.

7. Pringsheim T, Okun MS, Müller-Vahl K, *et al.* Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. *Neurology* 2019;**92**:896–906

8. Ott, D., Siddarth, P., Gurbani, S., Koh, S., Tournay, A., Shields, W. D., et al. (2003). Behavioral disorders in pediatric epilepsy: Unmet psychiatric need. Epilepsia,44(4), 591–597.

9. Ford T, Goodman R, Meltzer H. The British Child and Adolescent Mental Health Survey 1999: the prevalence of DSM-IV disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2003;42:1203-1211.

10. Goodman A, Heiervang, E., Collishaw, S., Goodman, R., . The 'DAWBA bands' as an orderedcategorical measure of child mental health: description and validation in British and Norwegian samples. Soc Psychiatry Psychiatr Epidemiol 2011;46:521-532.

11. Moore, D. A., Nunns, M., Shaw, L., Rogers, M., Walker, E., Ford, T., et al. (2019). Interventions to improve the mental health of children and young people with long-term physical conditions: linked evidence syntheses. *Health Technology Assessment (Winchester, England),23*(22), 1–164. https://doi.org/10.3310/hta23220.

12. Brady AM, Deighton J, Stansfeld S. Psychiatric outcomes associated with chronic illness in adolescence: A systematic review. J Adolesc. 2017 Aug;59:112-123.

13. Cavanna AE, Termine C. Tourette syndrome. Advances in experimental medicine and biology 2012;724:375-383.

14. Angold A, Erkanli A, Copeland W, Goodman R, Fisher PW, Costello EJ. Psychiatric diagnostic interviews for children and adolescents: a comparative study. Journal of the American Academy of Child and Adolescent Psychiatry 2012;51:506-517.

15. Groth C, Mol Debes N, Rask CU, Lange T, Skov L. Course of Tourette Syndrome and Comorbidities in a Large Prospective Clinical Study. Journal of the American Academy of Child and Adolescent Psychiatry 2017;56:304-312.

16. Foreman D, Morton S, Ford T. Exploring the clinical utility of the Development And Well-Being Assessment (DAWBA) in the detection of hyperkinetic disorders and associated diagnoses in clinical practice. Journal of child psychology and psychiatry, and allied disciplines 2009;50:460-470.

17. Patel, V., Belkin, G. S., Chockalingam, A., Cooper, J., Saxena, S., & Unützer, J. (2013). Grand challenges: Integrating mental health services into priority health care platforms. *PLoS Medicine*,10(5), e1001448.

18. <u>https://youthinmind.com/products-and-services/sdq/#</u>)

Table 1: Demographic data across all cohorts in the study

	Tic cohort	Non-tic MD	Emergency	Neurology	Community
		cohort	control	control	control ⁴
Total (n=)	158	102	100	37	10438
Australian (n=)	83	97	100	37	0
UK (n=)	75	5	0	0	10.438
Gender Male	127 (80.4%)	47 (46.1%)	56 (56.0%)	19 (51.3%)	5212 (49.9%)
Age range	5-16y	5-16y	5-16y	5-16y	5-15y
Mean age	10.6y	10.9y	9.8y	12.3y	11y

Table 2. Non-tic MD cohort by primary and secondary movement phenomenon, with demographic data.

Primary movement phenomenon	n =	Secondary movement phenomenon	n =	Gender (male)	Mean age at onset (y)	Mean age at DAWBA (y)
Dystonia	66	Chorea	4	2 M	4.5	9.3
		Myoclonus	3	1 M	2.5	14.3
		Tremor	6	3 M	6	11.3
		Bradykinesia	4	1 M	4.2	10
		Stereotypy	2	0 M	2	12
		none	47	19 M	3.5	10.8
Chorea	12	Myoclonus	2	1 M	2.7	8
		none	10	5 M	5.5	12.5
Stereotypy	11	none	11	7 M	2.5	8.5
Myoclonus	6	Dystonia	3	2M	1.7	8
		none	3	3 M	4	10.3
Tremor	5	none	5	2 M	10	12.4
Bradykinesia	1	none	1	0M	15	15
Other (functional)	1	none	1	0 M	1	16
Total	102			46 M		10.9

	Tic cohort	Non-tic MD cohort	Emergency control	Neurology control	Community healthy control
Total (n=)	158.0	102.0	100.0	37.0	10 438
Any psychiatric disorder (%)	41.8	39.2	18.0	29.7	9.5
Any Anxiety disorder (%)	32.3	28.4	11.0	27.0	3.8
Sep Anxiety	11.4	7.8	3.0	2.7	1.2
Social phobia	1.3	4.9	2.0	5.4	0.3
Agoraphobia	0.6	0.0	0.0	0.0	0.1
OCD	8.9	0.0	0.0	0.0	0.3
Gen anxiety	3.2	5.9	0.0	8.1	0.7
Specific phobia	3.8	3.9	4.0	2.7	1.0
Panic disorder	2.5	1.0	1.0	2.1	0.1
PTSD	0.0	1.0	1.0	0.0	0.1
Other anxiety	1.9	3.9	0.0	5.4	0.9
Depressive disorder (%)	3.2	4.9	1.0	2.7	0.9
Major depression	3.2	4.0	0.0	2.7	0.7
Other depression		0.0	0.0	0.0	0.2
Disruptive disorder (%)	8.8	13.7	5.0	13.5	5.9
ADHD combined	0.0	3.9	4.0	5.4	1.4
ADHD hyperactive	5.1	1.0	1.0	8.1	0.2
ADHD inattentive	3.8	9.8	0.0	0.0	0.7
Oppositional/conduct disorder (%)	17.7	2.9	4.0	2.7	3.8
ODD	17.7	6.9	4.0	2.7	2.3
Conduct	1.3	2.9	0.0	0.0	1.5
Social (%)	0.0	0.0	0.0	0.0	0.0
Selective mutism	0.0	0.0	0.0	0.0	0.0
Attachment disorder	0.0	0.0	0.0	0.0	0.0

Table 3. All psychiatric disorder groups and subgroups (DSM-5) in all cohorts

PDD/Autism (%)	3.8	2.0	0.0	5.4	0.3
Eating disorders (%)	0.0	0.0	0.0	0.0	0.1

OCD: Obsessive-compulsive disorder, PTSD: post-traumatic stress disorder, ADHD: attention deficit hyperactivity disorder, ODD: oppositional defiant disorder, PDD: pervasive developmental disorder.

Primary movement	n =	Patients with DSM-5	Specific diagnoses present
disorder		psychiatry (%)	
All dystonia	66	22 (33%)	Separation anxiety (5), social phobia (5), specific phobia (4), ADHD combined (3), ADHD inattentive (3), ODD (3), generalised anxiety (2), other anxiety (1), Major depression (1), ADHD hyperactive (1)
All chorea	12	8 (66.7%)	Separation anxiety (1), other anxiety (1) bipolar/mania (1), major depression (2), ADHD inattentive (1), ODD (3) conduct disorder (1
All myoclonus	6	1 (16.7%)	ADHD combined (1)
All tremor	5	3 (60.0%)	Generalised anxiety (1), panic disorder (1), major depression (1)
All bradykinesia	1	0 (0%)	-
All stereotypy	11	5 (45.5%)	Generalised anxiety (1), ADHD inattentive (3), ODD (1) PDD/Autism (2)
All other (functional)	1	1 (100%)	Generalised anxiety (1), PTSD (1), major depression (1) ADHD, conduct disorder
All clinical phenomena	102	40 (39.2%)	

Table 4: Rates and types of DSM-5 diagnoses in the non-tic movement cohort (n=102) by movement disorder phenotype

Table 5. Rate of psychiatry and specific psychiatric diagnoses presented by movement disorder aetiology

Aetiology	n =	Patients with psychiatry (%)	Specific diagnoses present
All neurotransmitter	13	3 (23.1%)	Generalised anxiety disorder (2), separation anxiety (1), conduct disorder (1)
Dopa responsive dystonia (GTP cyclohydrolase deficiency)	4	0	
Dopa responsive dystonia (gene negative)	3	2	Generalised anxiety (2), conduct disorder (1)
Tyrosine hydroxylase deficiency	3	1	Separation anxiety (1)
6 PTPS deficiency	3	0	-
All proven genetic	24	13 (45.1%)	Separation anxiety (4), ADHD inattentive (3), ODD (3), other anxiety (2), social phobia (1), specific phobia (1), major depression (1), ADHD combined (1), ODD (1)
KMT2B dystonia	2	2	Separation anxiety (1), social phobia (1), ADHD combined (1), ADHD inattentive (1)
TBC1D24 dystonia	1	0	-
Myoclonus dystonia (SCGE)	7	3	Specific phobia (1), other anxiety (1), ADHD inattentive (1)
GNB1 dystonia	1	0	
Glutaric acidura type 1	2	1	Separation anxiety (1)
Paroxysmal kinesiogenic dystonia (PRRT2)	4	2	Major depression (1), ODD (1)
Benign hereditary chorea	5	4	Separation anxiety, (1) other anxiety (1), ADHD inattentive (1), ODD (2)
Wilsons disease	1		
Juvenile huntingtins disease	1	1	Separation anxiety (1)

Dystonia - gene negative11bphobia (1), ADHD combined (1), ADHD hyperactive (1), ODD (1)Chorea - gene negative10Myoclonus - gene negative21ADHD combined (1)Tremor gene negative42Generalised anxiety (1) panic disorder (1), major depression (1)All immune114(36.4%)Social phobia (2), major depression (2), Bipolar/mania (1) ADHD combined (1), ODD (1)Sydenham's chorea22Bipolar/mania (1), Major depression (2)Antiphospholipid chorea100Basal ganglia encephalitis (Dopamine 2 Receptor Antibody positive)2Social phobia (2) ADHD combined (1), ODD (1)Rasmussen encephalitis syndrome10-Acute immune akinetc psychotic syndrome20-All multifactorial (dyskinetic CP group)226 (27.3%)ADHD inattentive (2), specific phobia (2), separation anxiety (1), social phobia (1)Prematurity defined as cause74Separation anxiety (1), social phobia (1), specific phobia (1), ADHD inattentive (2)Vascular event (in utero or neonatal)400	All suspected genetic	18	9(50%)	Separation anxiety (2), generalised anxiety (2), social phobia, (1), , specific phobia (1), major depression (1), panic disorder (1), ADHD combined (2), ADHD hyperactive (1), ODD (1)
Myoclonus - gene negative21ADHD combined (1)Tremor gene negative42Generalised anxiety (1) panic disorder (1), major depression (1)All immune114(36.4%)Social phobia (2), major depression (2), Bipolar/mania (1) ADHD combined (1), ODD (1)Sydenham's chorea22Bipolar/mania (1) ADHD combined (1), ODD (1)Sydenham's chorea100Basal ganglia encephalitis (Dopamine 2 Receptor Antibody positive)42Social phobia (2) ADHD combined (1), ODD (1)Rasmussen encephalitis with hemidystonia10-Opsoclonus myoclonus syndrome20-Acute immune akinetc psychotic syndrome10-All multifactorial 	Dystonia - gene negative	11	6	social phobia, (1), generalised anxiety (1), specific phobia (1), ADHD combined (1), ADHD
negative21ADHD combined (1)Tremor gene negative42Generalised anxiety (1) panic disorder (1), major depression (1)All immune114(36.4%)Social phobia (2), major depression (2), Bipolar/mania (1) ADHD combined (1), ODD (1)Sydenham's chorea22Bipolar/mania (1), major depression (2)Antiphospholipid chorea100Basal ganglia encephalitis (Dopamine 2 Receptor Antibody positive)42Social phobia (2) ADHD combined (1), ODD (1)Rasmussen encephalitis with hemidystonia10-Opsoclonus myoclonus syndrome20-Acute immune akinetc psychotic syndrome10-All multifactorial (dyskinetic CP group)226 (27.3%)Separation anxiety (1), generalised anxiety (1), social phobia (1)Prematurity defined as cause74Separation anxiety (1), social phobia (1), specific phobia (1), ADHD inattentive (2)Vascular event (in utero or neonatal)400	Chorea - gene negative	1	0	
Tremor gene negative42depression (1)All immune114(36.4%)Social phobia (2), major depression (2), Bipolar/mania (1) ADHD combined (1), ODD (1)Sydenham's chorea22Bipolar/mania (1), major depression (2)Antiphospholipid chorea10Basal ganglia encephalitis (Dopamine 2 Receptor Antibody positive)42Social phobia (2) ADHD combined (1), ODD (1)Rasmussen encephalitis with hemidystonia10-Opsoclonus myoclonus syndrome20-Acute immune akinetc psychotic syndrome10-All multifactorial (dyskinetic CP group)226 (27.3%)ADHD inattentive (2), specific phobia (2), separation anxiety (1), social phobia (1)Prematurity defined as cause74Separation anxiety (1), social phobia (1), specific phobia (1), ADHD inattentive (2)Vascular event (in utero or neonatal)40		2	1	ADHD combined (1)
All immune114(36.4%)Bipolar/mania (1) ADHD combined (1), ODD (1)Sydenham's chorea22Bipolar/mania (1), major depression (2)Antiphospholipid chorea10Basal ganglia encephalitis (Dopamine 2 Receptor Antibody positive)42Social phobia (2) ADHD combined (1), ODD (1)Rasmussen encephalitis with hemidystonia10-Opsoclonus myoclonus syndrome20-Acute immune akinetc psychotic syndrome10-All multifactorial (dyskinetic CP group)226 (27.3%)ADHD inattentive (2), specific phobia (2), separation anxiety (1), social phobia (1)Prematurity defined as cause74Separation anxiety (1), social phobia (1), specific phobia (1), ADHD inattentive (2)Vascular event (in utero or neonatal)400	Tremor gene negative	4	2	Generalised anxiety (1) panic disorder (1), major depression (1)
Antiphospholipid chorea10Basal ganglia encephalitis (Dopamine 2 Receptor Antibody positive)42Social phobia (2) ADHD combined (1), ODD (1)Rasmussen encephalitis with hemidystonia10-Opsoclonus myoclonus syndrome20-Acute immune akinetc psychotic syndrome10-All multifactorial (dyskinetic CP group)226 (27.3%)ADHD inattentive (2), specific phobia (2), social phobia (1)Prematurity defined as cause74Separation anxiety (1), social phobia (1), specific phobia (1), ADHD inattentive (2)	All immune	11	4(36.4%)	Social phobia (2), major depression (2), Bipolar/mania (1) ADHD combined (1), ODD (1)
Basal ganglia encephalitis (Dopamine 2 Receptor Antibody positive) Rasmussen encephalitis with hemidystonia 1 0 Opsoclonus myoclonus syndrome 2 0 Acute immune akinetc psychotic syndrome 1 0 Acute immune akinetc psychotic syndrome 2 6 (27.3%) ADHD inattentive (2), specific phobia (2), separation anxiety (1), generalised anxiety (1), social phobia (1) Prematurity defined as cause 7 4 0	Sydenham's chorea	2	2	Bipolar/mania (1), major depression (2)
encephalitis (Dopamine 2 Receptor Antibody positive)42Social phobia (2) ADHD combined (1), ODD (1)Rasmussen encephalitis with hemidystonia10-Opsoclonus myoclonus 	Antiphospholipid chorea	1	0	
with hemidystonia10-Opsoclonus myoclonus syndrome20-Acute immune akinetc psychotic syndrome10-Acute immune akinetc psychotic syndrome10-All multifactorial (dyskinetic CP group)226 (27.3%)ADHD inattentive (2), specific phobia (2), separation anxiety (1), generalised anxiety (1), social phobia (1)Prematurity defined as cause74Separation anxiety (1), social phobia (1), specific phobia (1), ADHD inattentive (2)Vascular event (in utero or neonatal)40	encephalitis (Dopamine 2 Receptor Antibody	4	2	Social phobia (2) ADHD combined (1), ODD (1)
syndrome20-Acute immune akinetc psychotic syndrome10-All multifactorial (dyskinetic CP group)226 (27.3%)ADHD inattentive (2), specific phobia (2), separation anxiety (1), generalised anxiety (1), 	-	1	0	-
psychotic syndrome10-All multifactorial (dyskinetic CP group)226 (27.3%)ADHD inattentive (2), specific phobia (2), separation anxiety (1), generalised anxiety (1), social phobia (1)Prematurity defined as cause74Separation anxiety (1), social phobia (1), specific phobia (1), ADHD inattentive (2)Vascular event (in utero or neonatal)40		2	0	-
All multifactorial (dyskinetic CP group)226 (27.3%)separation anxiety (1), generalised anxiety (1), social phobia (1)Prematurity defined as cause74Separation anxiety (1), social phobia (1), specific phobia (1), ADHD inattentive (2)Vascular event (in utero or neonatal)40		1	0	-
cause 7 4 phobia (1), ADHD inattentive (2) Vascular event (in utero or neonatal) 0		22	6 (27.3%)	separation anxiety (1), generalised anxiety (1),
or neonatal)	•	7	4	Separation anxiety (1), social phobia (1), specific phobia (1), ADHD inattentive (2)
Kernicterus 3 1 Generalised anxiety (1)		4	0	
	Kernicterus	3	1	Generalised anxiety (1)

Functional movement disorder	3	1(33.3%)	depression (1), ADHD inattentive (1), conduct disorder (1)
			Generalised anxiety (1), PTSD, (1), major
Stereotypy (All developmental)	11	4(36.4%)	Generalised anxiety (1), ADHD, inattentive (2) ODD (1), PDD/autism (2)
Unknown	4	0	-
encephalopathy or traumatic delivery	4	1	ADHD inattentive (1), specific phobia (1)

102 40 (39.2%)

Figure 1: The percentage of patients from each group who had any DSM-5 psychiatric diagnosis, any anxiety disorder, any disruptive disorder or any oppositional disorder. Significant statistical associations are highlighted (*)